Werkgroep Cardiologische centra Nederland English

dal-GenE (Follow up)

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS). The Dal-GenE trial
Middel
dalcetrapib
Populatie
ASCVD
Fase
III
Jaar aanvang
2015
Meer informatie
ClinicalTrials.gov

Studiedirecteur

drs. H.P. Swart (Cardioloog)
Sneek, D&A Research and Genetics